Breaking News Instant updates and real-time market news.

TSRO

TESARO

$117.91

18.65 (18.79%)

, MYGN

Myriad Genetics

$18.87

-2.475 (-11.60%)

13:25
10/11/16
10/11
13:25
10/11/16
13:25

TESARO failed to block Myriad press release, Bloomberg reports

A Manhattan district judge denied TESARO's (TSRO) attempt to block its partner Myriad Genetics (MYGN) from releasing a press release on the niraparib trial results. Both companies issued press releases on October 8.

TSRO

TESARO

$117.91

18.65 (18.79%)

MYGN

Myriad Genetics

$18.87

-2.475 (-11.60%)

  • 06

    Nov

  • 11

    Jan

TSRO TESARO
$117.91

18.65 (18.79%)

10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating
10/10/16
RBCM
10/10/16
NO CHANGE
RBCM
TESARO price target raised to $128 from $122 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.
MYGN Myriad Genetics
$18.87

-2.475 (-11.60%)

08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.
10/10/16
10/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

RBS

RBS

$5.90

-0.36 (-5.75%)

10:43
02/24/17
02/24
10:43
02/24/17
10:43
Periodicals
RBS CEO criticizes former exec's intention to join lawsuit, Bloomberg says »

The Royal Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$45.08

-0.15 (-0.33%)

10:41
02/24/17
02/24
10:41
02/24/17
10:41
Options
Activision short-term calls active as shares tick higher »

Activision short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DOC

Physicians Realty Trust

$20.01

0.1 (0.50%)

10:40
02/24/17
02/24
10:40
02/24/17
10:40
Syndicate
Breaking Syndicate news story on Physicians Realty Trust »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

10:39
02/24/17
02/24
10:39
02/24/17
10:39
Conference/Events
CLSA technology/internet analyst holds an analyst/industry conference call »

Technology Analyst James…

RY

Royal Bank of Canada

$74.47

-0.41 (-0.55%)

10:37
02/24/17
02/24
10:37
02/24/17
10:37
Periodicals
RBC places Asia wealth business under review, Reuters reports »

Royal Bank of Canada has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SB

Safe Bulkers

$1.38

0.009 (0.66%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Upgrade
Safe Bulkers rating change  »

Safe Bulkers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 22

    Mar

STX

Seagate

$47.39

0.04 (0.08%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

10:35
02/24/17
02/24
10:35
02/24/17
10:35
General news
The 3.7% U.S. January new home sales bounce »

The 3.7% U.S. January new…

SQ

Square

$17.23

0.075 (0.44%)

, TEX

Terex

$29.53

-0.38 (-1.27%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

SQ

Square

$17.23

0.075 (0.44%)

TEX

Terex

$29.53

-0.38 (-1.27%)

AERI

Aerie Pharmaceuticals

$44.25

-0.2 (-0.45%)

CLSD

Clearside Biomedical

$6.90

-0.29 (-4.03%)

PSTB

Park Sterling Bank

$12.07

-0.03 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

  • 21

    Mar

  • 21

    Mar

  • 15

    May

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

, W

Wayfair

$38.32

-0.265 (-0.69%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

W

Wayfair

$38.32

-0.265 (-0.69%)

RIG

Transocean

$14.06

-0.25 (-1.75%)

GT

Goodyear Tire

$35.50

-0.45 (-1.25%)

JACK

Jack in the Box

$96.70

-6.9 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$13.44

-0.25 (-1.83%)

, AMCX

AMC Networks

$59.84

2.34 (4.07%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WEN

Wendy's

$13.44

-0.25 (-1.83%)

AMCX

AMC Networks

$59.84

2.34 (4.07%)

CHK

Chesapeake

$5.81

0.055 (0.96%)

INTU

Intuit

$120.70

1.27 (1.06%)

HP

Helmerich & Payne

$68.53

-0.24 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

, NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Hot Stocks
Citron closes NVIDIA short, shifts focus to Mobileye »

Andrew Left's Citron…

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
General news
Michigan sentiment slipped to an upwardly-revised 96.3 »

Michigan sentiment…

ELNK

EarthLink

$5.85

0.04 (0.69%)

, WIN

Windstream

$7.29

0.07 (0.97%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.85

0.04 (0.69%)

WIN

Windstream

$7.29

0.07 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Wells Fargo housing analyst holds an analyst/industry conference call »

Senior Housing Analyst…

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
UBS pharma and medical devices analysts hold an analyst/industry conference call »

Major & Specialty…

JNJ

Johnson & Johnson

$122.19

1.2901 (1.07%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
CLSA financial tech analyst holds an analyst/industry conference call »

Financial Technology…

CLVS

Clovis

$57.71

-3.48 (-5.69%)

10:22
02/24/17
02/24
10:22
02/24/17
10:22
Hot Stocks
Clovis reports allegations of misconduct, which it calls 'unfounded' »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$5.85

0.095 (1.65%)

10:21
02/24/17
02/24
10:21
02/24/17
10:21
Options
Renewed interest in Chesapeake Apr 7 calls »

Renewed interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

10:20
02/24/17
02/24
10:20
02/24/17
10:20
General news
Treasury Action: yields rebounded slightly »

Treasury Action: yields…

WIN

Windstream

$7.29

0.07 (0.97%)

, ELNK

EarthLink

$5.85

0.04 (0.69%)

10:20
02/24/17
02/24
10:20
02/24/17
10:20
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.29

0.07 (0.97%)

ELNK

EarthLink

$5.85

0.04 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

MBLY

Mobileye

$46.81

-1.335 (-2.77%)

10:19
02/24/17
02/24
10:19
02/24/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Mobileye »

Citron sees Mobileye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

$NSD

NASDAQ Market Internals

10:17
02/24/17
02/24
10:17
02/24/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$23.48

-0.27 (-1.14%)

10:16
02/24/17
02/24
10:16
02/24/17
10:16
Options
Micron put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 20

    Mar

  • 23

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.